Sonoma Pharmaceuticals appoints CEO to board, amends exec agreements, CFO to resign amid office consolidation

Sonoma Pharmaceuticals, Inc.

CEO Amy Trombly appointed to board effective July 22, 2022; amended employment agreement with severance of one-time base salary.
COO Bruce Thornton agreement amended; change-in-control bonus of 50% of base salary added.
CFO Jerry Dvonch resigns effective on/before Dec 31, 2022; severance of $100,000 plus COBRA and equity acceleration.
Annual bonus grants approved: $162,500 for Trombly, $150,000 for Thornton.
Company consolidating to Boulder, CO; closing Woodstock, GA office as part of cost-cutting.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jerry Dvonch

Chief Financial Officer

SNOA · Sonoma Pharmaceuticals, Inc.

Effective: 2022-12-31
Filed: July 22, 2022, 7:59 PM ET

In connection with the Woodstock office closure, Mr. Jerry Dvonch resigned as our Chief Financial Officer.

Appointed

Amy Trombly

Director

SNOA · Sonoma Pharmaceuticals, Inc.

Effective: 2022-07-22
Filed: July 22, 2022, 7:59 PM ET

Effective July 22, 2022, the Company’s Board of Directors appointed Amy Trombly, our Chief Executive Officer, to serve as a member of our Board of Directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jerry Dvonch resigned as Chief Financial Officer at Sonoma Pharmaceuticals, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

In connection with the Woodstock office closure, Mr. Jerry Dvonch resigned as our Chief Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Amy Trombly was appointed as Director at Sonoma Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

Effective July 22, 2022, the Company’s Board of Directors appointed Amy Trombly, our Chief Executive Officer, to serve as a member of our Board of Directors.

View on SEC.gov

Sonoma Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-22-005083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.